Revlimid (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. .

Medicinal name:
  • Lenalidomide 25 MG Oral Capsule [Revlimid]
  • Lenalidomide 15 MG Oral Capsule [Revlimid]
  • Lenalidomide 10 MG Oral Capsule [Revlimid]
  • Lenalidomide 2.5 MG Oral Capsule [Revlimid]
  • Lenalidomide 20 MG Oral Capsule [Revlimid]
  • Lenalidomide 5 MG Oral Capsule [Revlimid]

Revlimid - Pharmacology:

The mechanism of action of lenalidomide remains to be fully characterized, however it has been demonstrated that lenalidomide inhibits the expression of cyclooxygenase-2 (COX-2), but not COX-1, in vitro.

Revlimid mini report

Revlimid NDA
NDA - A product marketed under an approved New Drug Application
Start - Stop data
Start - Stop data
not occurred

Revlimid for patients

Patients should be counseled on lenalidomide’s potential risk of teratogenicity due to its structural similarity to thalidomide. Under the RevAssist SM program, patients may only acquire a prescription for REVLIMID® (lenalidomide) therapy through a controlled distribution program through contracted pharmacies. Female patients of childbearing potential will be educated and counseled on the requirements of the RevAssist SM program and the precautions to be taken to preclude fetal exposure to REVLIMID® (lenalidomide). Patients should become familiar with the REVLIMID® RevAssistSM educational materials, Patient Medication Guide, and direct any questions to their physician or pharmacist prior to starting REVLIMID® (lenalidomide) therapy.

Revlimid Interactions

Results from human in vitro metabolism studies and nonclinical studies show that REVLIMID® (lenalidomide) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that lenalidomide is not likely to cause or be subject to P450-based metabolic drug interactions in man.

Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of R- and S- warfarin. Co-administration of single 25-mg dose warfarin had no effect on the pharmacokinetics of total lenalidomide. Expected changes in laboratory assessments of PT and INR were observed after warfarin administration, but these changes were not affected by concomitant lenalidomide administration.

Revlimid Contraindications

Pregnancy: Category X

Due to its structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in pregnant women and women capable of becoming pregnant. When there is no alternative, females of childbearing potential may be treated with lenalidomide provided adequate precautions are taken to avoid pregnancy. Females must commit either to abstain continuously from heterosexual sexual intercourse or to use two methods of reliable birth control, including at least one highly effective method (e.g., IUD, hormonal contraception, tubal ligation, or partner’s vasectomy) and one additional effective method (e.g., latex condom, diaphragm, or cervical cap), beginning 4 weeks prior to initiating treatment with REVLIMID® (lenalidomide), during therapy with REVLIMID® (lenalidomide), during therapy delay, and continuing for 4 weeks following discontinuation of REVLIMID® (lenalidomide) therapy. If hormonal or IUD contraception is medically contraindicated, two other effective or highly effective methods may be used.

Females of childbearing potential being treated with REVLIMID® (lenalidomide) should have pregnancy testing (sensitivity of at least 50 mIU/mL). The first test should be performed within 10-14 days and the second test within 24 hours prior to beginning REVLIMID® (lenalidomide) therapy and then weekly during the first month of REVLIMID® (lenalidomide), then monthly thereafter in women with regular menstrual cycles or every 2 weeks in women with irregular menstrual cycles. Pregnancy testing and counseling should be performed if a patient misses her period or if there is any abnormality in menstrual bleeding. If pregnancy occurs, REVLIMID® (lenalidomide) must be immediately discontinued. Under these conditions, the patient should be referred to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling.

REVLIMID® (lenalidomide) is contraindicated in any patients who have demonstrated hypersensitivity to the drug or its components.

Manufacturers name:

  • Celgene Corporation

Generic name, Overdose, Half Life Revlimid, Food Interactions, Chemical, etc..

Revlimid see also FDA report

Brand Names containing Lenalidomide

Chemical structure:
N N O N O O H H H H H H H H H H H H H C13H13N3O3 2D chemical structure C13H13N3O3 SVG | 2D structure Lenalidomide | [2-(Methyleneamine)-4-(4-Hydroxy-Benzylidine)-5-Oxo-4,5-Dihydro-Imidazol-1-Yl]-Acetaldehyde | chemical names, chemical properties, classification C13H13N3O3